EyePoint Pharmaceuticals ( NASDAQ:EYPT – Get Rating ) was downgraded by StockNews.com from a 'hold' rating to a 'sell' rating in a research report issued on Monday. Several other equities analysts also recently issued reports on EYPT. Chardan Capital restated a 'buy' rating and set a $21.00 price objective on shares of EyePoint Pharmaceuticals in a report on Friday, March 3rd. Robert W. Baird started coverage on shares of EyePoint Pharmaceuticals in a report on Thursday. They set an 'outperform' rating and a $33.

https://www.dailypolitical.com/2023/04/24/eyepoint-pharmaceuticals-nasdaqeypt-downgraded-to-sell-at-stocknews-com.html

#dailypolitical